NorthRock Partners LLC Raises Holdings in Bristol-Myers Squibb (NYSE:BMY)

NorthRock Partners LLC grew its position in Bristol-Myers Squibb (NYSE:BMY - Free Report) by 192.8% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 26,839 shares of the biopharmaceutical company's stock after buying an additional 17,672 shares during the period. NorthRock Partners LLC's holdings in Bristol-Myers Squibb were worth $1,518,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Fiduciary Alliance LLC acquired a new stake in shares of Bristol-Myers Squibb in the 4th quarter worth $253,000. Wedmont Private Capital raised its stake in Bristol-Myers Squibb by 29.5% in the fourth quarter. Wedmont Private Capital now owns 10,487 shares of the biopharmaceutical company's stock valued at $586,000 after buying an additional 2,392 shares during the last quarter. BCS Wealth Management acquired a new stake in Bristol-Myers Squibb in the fourth quarter worth about $329,000. Rosenberg Matthew Hamilton grew its stake in shares of Bristol-Myers Squibb by 68.6% during the fourth quarter. Rosenberg Matthew Hamilton now owns 1,705 shares of the biopharmaceutical company's stock worth $96,000 after acquiring an additional 694 shares during the last quarter. Finally, 626 Financial LLC increased its holdings in shares of Bristol-Myers Squibb by 7.5% during the fourth quarter. 626 Financial LLC now owns 10,053 shares of the biopharmaceutical company's stock valued at $569,000 after acquiring an additional 699 shares in the last quarter. Hedge funds and other institutional investors own 76.41% of the company's stock.

Bristol-Myers Squibb Stock Performance

Shares of NYSE BMY traded up $0.96 during midday trading on Friday, reaching $46.77. 12,103,063 shares of the stock were exchanged, compared to its average volume of 13,232,604. The company has a quick ratio of 1.15, a current ratio of 1.25 and a debt-to-equity ratio of 2.90. The firm has a market cap of $95.18 billion, a price-to-earnings ratio of -10.58, a PEG ratio of 2.07 and a beta of 0.39. The firm has a 50-day simple moving average of $53.05 and a two-hundred day simple moving average of $55.99. Bristol-Myers Squibb has a twelve month low of $39.35 and a twelve month high of $63.33.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last released its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 EPS for the quarter, beating the consensus estimate of $1.50 by $0.30. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. The company had revenue of $11.20 billion for the quarter, compared to analyst estimates of $10.77 billion. During the same quarter last year, the business earned ($4.40) earnings per share. The firm's revenue was down 5.6% on a year-over-year basis. As a group, analysts anticipate that Bristol-Myers Squibb will post 6.74 EPS for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, May 1st. Investors of record on Friday, April 4th were issued a $0.62 dividend. The ex-dividend date of this dividend was Friday, April 4th. This represents a $2.48 dividend on an annualized basis and a yield of 5.30%. Bristol-Myers Squibb's payout ratio is 92.88%.

Wall Street Analyst Weigh In

A number of analysts recently commented on the stock. Cantor Fitzgerald reiterated a "neutral" rating and issued a $55.00 target price on shares of Bristol-Myers Squibb in a research note on Tuesday, April 22nd. Piper Sandler started coverage on shares of Bristol-Myers Squibb in a research note on Tuesday, April 22nd. They set an "overweight" rating and a $65.00 price objective for the company. William Blair reissued a "market perform" rating on shares of Bristol-Myers Squibb in a research report on Friday, April 25th. Wells Fargo & Company lifted their price target on Bristol-Myers Squibb from $60.00 to $62.00 and gave the stock an "equal weight" rating in a research report on Friday, February 7th. Finally, Argus raised Bristol-Myers Squibb to a "hold" rating in a report on Friday, April 25th. Two equities research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, five have given a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat.com, Bristol-Myers Squibb has a consensus rating of "Hold" and an average price target of $58.00.

Insiders Place Their Bets

In other Bristol-Myers Squibb news, EVP Samit Hirawat bought 4,250 shares of the firm's stock in a transaction dated Friday, April 25th. The shares were purchased at an average price of $47.58 per share, for a total transaction of $202,215.00. Following the transaction, the executive vice president now directly owns 83,513 shares of the company's stock, valued at approximately $3,973,548.54. This represents a 5.36% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 0.09% of the stock is currently owned by company insiders.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.